329 related articles for article (PubMed ID: 33303407)
1. Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
Shea AK; Wang DY; Snelgrove JW; Dalfen A; Hewko S; Murphy KE
J Obstet Gynaecol Can; 2021 Jun; 43(6):726-732. PubMed ID: 33303407
[TBL] [Abstract][Full Text] [Related]
2. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication.
Kaltenbach K; Holbrook AM; Coyle MG; Heil SH; Salisbury AL; Stine SM; Martin PR; Jones HE
Addiction; 2012 Nov; 107 Suppl 1(0 1):45-52. PubMed ID: 23106926
[TBL] [Abstract][Full Text] [Related]
3. Neonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score.
Forsberg L; Navér L; Gustafsson LL; Wide K
PLoS One; 2014; 9(11):e111327. PubMed ID: 25365553
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome.
Klinger G; Frankenthal D; Merlob P; Diamond G; Sirota L; Levinson-Castiel R; Linder N; Stahl B; Inbar D
J Perinatol; 2011 Sep; 31(9):615-20. PubMed ID: 21311497
[TBL] [Abstract][Full Text] [Related]
5. Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.
Yang A; Ciolino JD; Pinheiro E; Rasmussen-Torvik LJ; Sit DKY; Wisner KL
J Clin Psychiatry; 2017 May; 78(5):605-611. PubMed ID: 28570796
[TBL] [Abstract][Full Text] [Related]
6. SSRI treatment during pregnancy: are we asking the right questions?
Wisner KL
Depress Anxiety; 2010 Aug; 27(8):695-8. PubMed ID: 20694964
[No Abstract] [Full Text] [Related]
7. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Maternal-Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015.
Dave CV; Goodin A; Zhu Y; Winterstein A; Wang X; Alrwisan A; Hartzema A
Pharmacotherapy; 2019 Oct; 39(10):1005-1011. PubMed ID: 31361913
[TBL] [Abstract][Full Text] [Related]
9. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.
Levinson-Castiel R; Merlob P; Linder N; Sirota L; Klinger G
Arch Pediatr Adolesc Med; 2006 Feb; 160(2):173-6. PubMed ID: 16461873
[TBL] [Abstract][Full Text] [Related]
10. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors.
Nordeng H; Lindemann R; Perminov KV; Reikvam A
Acta Paediatr; 2001 Mar; 90(3):288-91. PubMed ID: 11332169
[TBL] [Abstract][Full Text] [Related]
11. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome.
Klinger G; Merlob P
Isr J Psychiatry Relat Sci; 2008; 45(2):107-13. PubMed ID: 18982836
[TBL] [Abstract][Full Text] [Related]
12. Neonatal and childhood neurodevelopmental, health and educational outcomes of children exposed to antidepressants and maternal depression during pregnancy: protocol for a retrospective population-based cohort study using linked administrative data.
Singal D; Brownell M; Chateau D; Ruth C; Katz LY
BMJ Open; 2016 Nov; 6(11):e013293. PubMed ID: 27899401
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
Oberlander TF; Misri S; Fitzgerald CE; Kostaras X; Rurak D; Riggs W
J Clin Psychiatry; 2004 Feb; 65(2):230-7. PubMed ID: 15003078
[TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects.
Ornoy A; Koren G
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):247-259. PubMed ID: 29345153
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study.
Pogliani L; Falvella FS; Cattaneo D; Pileri P; Moscatiello AF; Cheli S; Baldelli S; Fabiano V; Cetin I; Clementi E; Zuccotti G
Ther Drug Monit; 2017 Apr; 39(2):197-201. PubMed ID: 28045861
[TBL] [Abstract][Full Text] [Related]
16. Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function.
Pawluski JL; Brain UM; Underhill CM; Hammond GL; Oberlander TF
Psychoneuroendocrinology; 2012 Jul; 37(7):1019-28. PubMed ID: 22177580
[TBL] [Abstract][Full Text] [Related]
17. Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in Florida.
Wang X; Zhu Y; Dave CV; Alrwisan AA; Voils SA; Winterstein AG
Pharmacotherapy; 2017 Jul; 37(7):806-813. PubMed ID: 28500694
[TBL] [Abstract][Full Text] [Related]
18. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database.
Gastaldon C; Arzenton E; Raschi E; Spigset O; Papola D; Ostuzzi G; Moretti U; Trifirò G; Barbui C; Schoretsanitis G
Psychol Med; 2023 Sep; 53(12):5645-5653. PubMed ID: 36128628
[TBL] [Abstract][Full Text] [Related]
19. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.
Moses-Kolko EL; Bogen D; Perel J; Bregar A; Uhl K; Levin B; Wisner KL
JAMA; 2005 May; 293(19):2372-83. PubMed ID: 15900008
[TBL] [Abstract][Full Text] [Related]
20. The effect of prenatal alcohol co-exposure on neonatal abstinence syndrome in infants born to mothers in opioid maintenance treatment.
Kreitinger C; Gutierrez H; Hamidovic A; Schmitt C; Sarangarm P; Rayburn WF; Leeman L; Bakhireva LN
J Matern Fetal Neonatal Med; 2016 Mar; 29(5):783-8. PubMed ID: 25758627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
